COVID-19: New triple antiviral drug combination shows early promise for treatment in phase 2 randomized trial
by Press Release from Outbreak News Today on (#538DP)
A two-week course of antiviral therapy with interferon beta-1b plus lopinavir-ritonavir and ribavirin, started within 7 days of showing COVID-19 symptoms, is safe and more effective at reducing the duration of viral shedding than lopinavir-ritonavir alone in patients with mild to moderate illness, according to the first randomised trial of this triple combination therapy involving [...]
The post COVID-19: New triple antiviral drug combination shows early promise for treatment in phase 2 randomized trial appeared first on Outbreak News Today.